Inactive Instrument

Other languages Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

IL0006290147

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	Apr. 11
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	Apr. 11
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	Apr. 04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics	Apr. 01
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple	Mar. 11
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing	Mar. 07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing	Mar. 07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing	Mar. 07
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing	Mar. 05
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing	Mar. 05
Teva Pharmaceutical Industries Insider Sold Shares Worth $270,176, According to a Recent SEC Filing	Mar. 01
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar	Feb. 26
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -	Feb. 26
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	Feb. 26
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA	Feb. 26
Teva Pharmaceutical's TEV-'574 Antibody Found to Be Safe in Studies	Feb. 20
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO	Feb. 20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT